跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 22 条关于
“Longboard”
全部
22
临床试验
3
药物
0
机构
1
资讯
18
去年
Longboard Pharmaceuticals Launches Phase 3 Trial of Bexicaserin for Dravet Syndrome
去年
Lundbeck to Acquire Longboard for $2.6 Billion, Bolstering Neuro-Rare Disease Pipeline
去年
Longboard Pharmaceuticals Initiates Phase 3 Trial of Bexicaserin for Dravet Syndrome
去年
Longboard Pharmaceuticals Advances Bexicaserin for Dravet Syndrome
去年
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion, Bolstering Dravet Syndrome Pipeline
去年
Longboard Pharmaceuticals Launches Phase 3 Trial of Bexicaserin for Developmental and Epileptic Encephalopathies
去年
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion, Bolstering Epilepsy Pipeline
2年前
Longboard's Bexicaserin Shows Sustained Seizure Reduction in DEE Patients
去年
Longboard Pharmaceuticals Initiates Phase III Trial of Bexicaserin for Developmental and Epileptic Encephalopathies
去年
Bexicaserin Shows Sustained Seizure Reduction in Developmental Epileptic Encephalopathies
第 1 页,共 2 页
上一页
下一页